Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
-
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
-
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
-
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
-
Abstract Published in ASCO 2024 Annual Meeting Book Showcases Validity of Belong.Life's Conversational AI Cancer Mentor 'Dave'
-
Orca Bio to Present Positive Clinical Outcomes with Orca-T in Patients with AML at 2024 ASCO Annual Meeting
-
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
-
City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
New Research Demonstrates the Importance of Genetic Testing for Many Cancers Not Currently Covered by Clinical Guidelines
-
Comvest Partners Announces $70 Million Senior Credit Facility For Nationwide Energy Partners to Support Growth Strategy
-
EMD Serono to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
-
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Socie
-
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
-
THE WALLA WALLA VALLEY BECOMES FIRST CERTIFIED BLUE ZONES COMMUNITY® IN WASHINGTON
-
OncoHost to Present Poster Demonstrating PROphet®'s Application in Multiple Cancer Indications at ASCO 2024
-
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
-
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer
-
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
-
Incendia Therapeutics Announces Upcoming Presentation with PathAI at the 2024 American Society of Clinical Oncology Annual Meeting
-
Klaviyo to Present at the William Blair Growth Stock Conference
-
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
-
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
-
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
-
MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT
-
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
-
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (
-
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
-
Dentalcorp Announces Annual General Meeting Voting Results
-
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
-
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
-
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
-
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
-
NVIDIA Announces Upcoming Event for Financial Community
-
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Ligand to Participate in Upcoming Investor Conferences
-
Park Aerospace Corp. Announces Date of Fiscal Year Earnings Release and Conference Call
-
CORRECTION FROM SOURCE: ArcStone Strengthens its Investment Banking Team with Strategic Hires
-
THOR Industries Announces Date For Its Fiscal 2024 Third Quarter Earnings Release
-
Diamonds de Canada Unveils the Lands Collection at JCK Show in Las Vegas
-
Our People: Lora Collins, Woman of Asphalt
-
Acme United Corporation Acquires the Assets of Elite First Aid
-
Ecora Resources PLC Announces Transaction in Own Shares
-
ValueZone Strengthens Resources for Traders in Current Bull Market
-
Smith-Midland Reports Fourth Quarter and Year End 2023 Financial Results
-
Genworth Financial Announces Results of Annual Meeting
-
Tanger Schedules Second Quarter 2024 Earnings Release and Conference Call


